Article Text

Download PDFPDF
Cohort study
Prothrombin complex concentrate safely reverses warfarin-related bleeding
  1. Huyen Tran1,
  2. Sanjeev Chunilal2
  1. 1 Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;
  2. 2 Department of Clinical Haematology, Monash Medical Centre, Melbourne, Australia
  1. Correspondence to Dr Huyen Tran, Department of Clinical Haematology, The Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004, Australia; huyen.tran{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


The incidence of major bleeding among patients receiving warfarin ranges from 1.35% to 3.4%, and intracranial haemorrhage (ICH) occurs in up to 0.7% of cases/annum.1 Therefore, effective strategies for warfarin reversal in patients with major bleeding are important. Historically, only fresh frozen plasma (FFP) and intravenous vitamin K1 have been available for emergency reversal, neither of which immediately restores vitamin K-dependent coagulation factors.2 FFP administration is often associated with lengthy delays and well-described potential risks.

Prothrombin complex concentrates (PCC) are plasma derived, virally inactivated clotting factors that can be used for reversing warfarin coagulopathy. They can broadly …

View Full Text


  • Competing interests None.